Tempus AI, Inc. (NASDAQ:TEM) COO Sells $234,803.16 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 2,868 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total value of $234,803.16. Following the completion of the transaction, the chief operating officer now directly owns 944,460 shares in the company, valued at approximately $77,322,940.20. This represents a 0.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $39.61, for a total value of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Stock Performance

TEM stock traded down $8.99 during mid-day trading on Thursday, hitting $76.72. The company had a trading volume of 20,409,815 shares, compared to its average volume of 14,385,644. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a 50-day moving average price of $49.75 and a 200 day moving average price of $51.44.

Institutional Trading of Tempus AI

Hedge funds have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC purchased a new stake in shares of Tempus AI during the 3rd quarter valued at about $1,367,000. China Universal Asset Management Co. Ltd. bought a new position in Tempus AI in the 4th quarter worth about $1,091,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Tempus AI in the 4th quarter worth about $178,000. Finally, Captrust Financial Advisors bought a new position in Tempus AI in the 3rd quarter worth about $2,726,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. William Blair downgraded shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Wolfe Research began coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, TD Cowen reissued a “buy” rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.